1. Introduction {#sec1-diagnostics-10-00253}
===============

Interstitial lung diseases (ILDs) are conditions characterized by an abnormal deposition of extracellular matrix and/or inflammatory cells in the interstitial space of the lung. They may be idiopathic or associated with a number of conditions, such as drugs and environmental exposure or autoimmune diseases (ADs) \[[@B1-diagnostics-10-00253]\]. The diagnostic assessment of ILDs can be challenging, considering the potential risk associated with a lung biopsy \[[@B2-diagnostics-10-00253]\]. In ADs-ILDs, the pulmonary manifestation may be the only clinical feature in the context of an incomplete form of the disease or the first manifestation of a systemic involvement \[[@B3-diagnostics-10-00253]\]. Currently, the gold standard for the diagnostic assessment of ILD is the multidisciplinary team (MDT), and, among these healthcare professionals, the presence of a rheumatologist demonstrated a significant improvement in the diagnostic performances, also reducing the number of invasive exams \[[@B4-diagnostics-10-00253]\]. The rheumatologist is therefore a useful member of the MDT, considering that connective tissue diseases (CTDs) and ADs are frequently associated with ILD. The principal radiographic pattern of CTD-ILD is nonspecific interstitial pneumonia (NSIP), but all patterns can be associated. Usual interstitial pneumonia (UIP) is the most frequent pattern in the course of rheumatoid arthritis (RA) and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and it may be present in the end-stage of the lung involvement in other CTDs \[[@B5-diagnostics-10-00253]\]. The correct diagnostic assessment of these conditions is crucial for the management of patients. Indeed, despite a similar (and almost indistinguishable) pattern, the UIP pattern associated with RA has a better prognosis compared to idiopathic pulmonary fibrosis (IPF). On the contrary, NSIP patterns associated with systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIMs) can have a poor prognosis \[[@B5-diagnostics-10-00253]\].

SSc and IIMs are characterized by the common presence of Raynaud's phenomenon (RP). This is a recurrent spasm of the terminal microcirculation, generally caused by a thermal cold shock, in which the fingers turn white (ischemic phase), blue (cyanotic phase) and red (revascularization phase) \[[@B6-diagnostics-10-00253]\]. Nailfold videocapillaroscopy (NVC) is a useful, economic and rapid tool generally used for the diagnostic assessment of RP as the primary or associated with CTDs \[[@B7-diagnostics-10-00253]\]. In the last few years, NVC has been useful also for the assessment of disease activity in SSc \[[@B8-diagnostics-10-00253],[@B9-diagnostics-10-00253],[@B10-diagnostics-10-00253]\] and in predicting lung involvement in CTDs \[[@B11-diagnostics-10-00253]\]. Moreover, NVC showed a scleroderma pattern also in antisynthetase antibodies syndrome (ASAS), independently of the presence of RP \[[@B12-diagnostics-10-00253]\]. ASAS is a CTD included in the IIMs, frequently associated with severe ILD, in which the diagnosis is challenging due to the lack of validated classification criteria and the difficulty in routinely performing the assessment for myositis-specific antibodies \[[@B13-diagnostics-10-00253]\].

The purpose of this study was to evaluate the performance of NVC in the diagnostic assessment of ILD patients.

2. Materials and Methods {#sec2-diagnostics-10-00253}
========================

This is a prospective study involving outpatient subjects recruited at the regional referral center for rare lung disease, for suspected ILD, conducted from January 2017 to July 2019. All the patients involved in the study underwent the same diagnostic approach.

The clinical assessment was performed by pulmonologists and rheumatologists together. During this assessment, an accurate anamnesis was collected, looking for any significant exposure (e.g., asbestos or a smoking habit), as well as clinical signs of CTDs. Considering the topic of the work, the assessment of RP was accurately performed. Patients were considered as having or not RP according to the international consensus criteria \[[@B14-diagnostics-10-00253]\]. During the clinical assessment, the patients underwent pulmonary function tests, including six-minute walk tests and, in some cases, blood--gas analysis. However, these procedures mainly have a prognostic, rather than a diagnostic, value for ILD patients \[[@B5-diagnostics-10-00253]\]. Therefore, although necessary for the disease management, these tests were not included in the study.

A basal serological profile was performed in all patients for diagnostic and therapeutic purposes. It included a complete blood cell count, erythrocyte sedimentation rate (ESR), C-reactive protein, urine test, aspartate transaminase (AST), alanine transaminase (ALT), creatine phosphokinase (CPK), lactic dehydrogenase (LDH), creatinine, serum protein electrophoresis, complement fractions C3 and C4, ANCA, anti-double-strain DNA (DsDNA), rheumatoid factor, anticitrullinated protein antibody (ACPA), antinuclear antibody (ANA) with a description of the pattern in indirect immunofluorescence and an extractable nuclear antigens (ENA) profile. The latter profile included the subsequent specificities: anti-Ro/SSA 60kD and 52kD, anti-La/SSB, Jo1, anti-Sm, anti-Scl70 and anti-RNP. Our anti-myositis profile included the following specificities: anti-Pm/Scl 75kD and 100kD, anti-Mi2, anti-Ku, anti-SRP, PL7, PL12, OJ, EJ and KS. This panel was tested in patients with at least one of these features: ANA positivity at any titre with a cytoplasmic, nucleolar or mitochondrial pattern; anti-SSA52kD positivity; increased AST, LDH and/or CPK; diagnosis of polymyalgia rheumatica (PMR) associated with ILD; the presence of giant capillaries (GCs) and/or avascular areas (AAs) in NVC in patients seronegative for SSc-related antibodies and bushy capillaries in NVC \[[@B15-diagnostics-10-00253],[@B16-diagnostics-10-00253],[@B17-diagnostics-10-00253],[@B18-diagnostics-10-00253]\].

For the radiological assessment, all patients underwent high-resolution computed tomography (HRCT) with a thickness ranging between 0.625 and 1.25 mm. The interpretation of patterns was made by experienced radiologists and pulmonologists following the current guidelines \[[@B19-diagnostics-10-00253]\].

NVC was performed with Videocap 5.0 Scalar Co. Ltd, Ds MediGroup, Milan, Italy examining all fingers, excluding the thumbs, using a videocapillaroscopy with a 200× magnification lens. Each finger was studied with 4 consecutive 1-mm fields images, successively stored and analyzed by the manufacturer's dedicated software. NVC was considered positive with the presence of giant capillaries (GCs, defined as capillaries with a nonaneurismal loop \>50 μm) or avascular areas (AAs, defined as distance \>500 μm between two consecutive capillaries). During NVC, although not used for the definition of NVC positivity, the presence of bushy capillaries (BCs, capillaries with multiple terminal loops directed in all directions) was reported as well. BCs are not specific for SSc, but they are associated with IIMs \[[@B17-diagnostics-10-00253]\]. [Figure 1](#diagnostics-10-00253-f001){ref-type="fig"} shows some exemplificative images of GCs, AAs and BCs. A final conclusion was made by a semi-quantitative analysis according to Cutolo's criteria \[[@B20-diagnostics-10-00253]\].

All the patients included in the study were evaluated by the MDT. This consensus allowed us to obtain the description of specific HRCT patterns in all patients, to discuss doubtful diagnoses and to evaluate the opportunity to perform second-level exams, including invasive procedures (e.g., bronchoscopy or biopsy), in order to reach a confident diagnosis. Patients that did not complete the above-mentioned diagnostic procedures or who did not undergo second-level examinations as suggested after the MDT, were considered as not definitely diagnosed and were therefore excluded from the study. All the diagnoses were made according to the latest version of the specific, validated classification criteria. ASAS does not currently have validated criteria; therefore, we used those proposed by Connors et al. \[[@B21-diagnostics-10-00253]\].

The study was approved by our local ethics committee (Ethics Committee Catania 1, n.0024182 cl.: TMP/10-2015, 27 May 2019), and written informed consent was signed by all the patients involved.

Statistical analysis was made using the IBM SPSS Statistics for Windows, Version 20.0 (Armonk, NY, USA: IBM Corp.). The enrollment of the patients was made in the regional referral center for rare lung diseases. Considering a total population of 5 million subjects, a prevalence of ILDs as 0.1% \[[@B22-diagnostics-10-00253]\], a confidence interval of 5 and a confidence level of 95%, we estimated the enrollment of a minimum of 357 ILD patients. Considering the heterogeneous group of ILD patients, the data were not adjusted for covariates (e.g., hypoxia, age, gender and BMI). Actually, none of these factors have been proven to influence significantly NVC \[[@B23-diagnostics-10-00253],[@B24-diagnostics-10-00253],[@B25-diagnostics-10-00253]\]. Conflicting results are also reported regarding the association between PFTs and NVC in SSc, no association was reported in IPF and evidences in other ILDs are totally lacking \[[@B26-diagnostics-10-00253],[@B27-diagnostics-10-00253],[@B28-diagnostics-10-00253],[@B29-diagnostics-10-00253]\].

The data were reported in percentages and mean (± standard deviation). The difference between the proportions of the groups was carried out by means of the Z-test.

For the evaluation of the predictive value in IIMs, we used a χ square test in order to verify the association between IIM and all the collected variables observed. Differences were considered statistically significant for *p* \< 0.05.

3. Results {#sec3-diagnostics-10-00253}
==========

After the exclusion of subjects who had not completed the appropriate diagnostic procedures (43 patients), we included 361 ILD patients. A brief presentation of these patients with their final diagnosis and HRCT patterns is reported in [Table 1](#diagnostics-10-00253-t001){ref-type="table"}.

NVC resulted positive (NVC+) in 64 (17.7%) of patients. A final diagnosis of CTD was made in 78.1% of these patients (89.1% considered an undifferentiated form together with specific CTDs). Of these patients, 31.5% showed an early pattern, whereas active and late patterns were respectively in 25% and 33.5% of patients. NVC+ patients were younger, with a prevalence of female gender and NSIP patterns. The prevalent final diagnosis was SSc, mixed CTD and IIMs. Clearly, RP was commonly reported in the NVC+ group, but it should be noted that 20 patients did not have RP (5.5% of the overall cohort and 31.3% of NVC+ group). Ten of these patients were classified as having CTD, whereas four as interstitial pneumonia with autoimmune features (IPAF). More details were reported in [Table 2](#diagnostics-10-00253-t002){ref-type="table"}.

The proportion of IPAF patients with NVC positivity was 9.5%, similar to that reported in RA, hypersensitivity pneumonia (HP), cryptogenic ILDs, exposure-related ILD, IPF and primary Sjögren's syndrome (pSS) (respectively, 0%, 0%, 3.1%, 5.6%, 5.7% and 17.6%; all *p* = not significant). Conversely, the proportion of NVC+ in IPAF patients was significantly lower than that reported in polymyositis/dermatomyositis (PM/DM), ASAS, overlap syndromes and SSc (respectively, PM/DM: 33%, X^2^ = 4.77 and *p* = 0.02; ASAS: 17%, X^2^ = 16.42 and *p* = 0.0001; overlap syndromes: 62.5%, X^2^ = 15.03 and *p* = 0.0001; SSc: 92.8%, X^2^ = 58.37 and *p* = \<0.0001). MCTD and SLE were not tested due to the presence of only two patients for each condition ([Figure 2](#diagnostics-10-00253-f002){ref-type="fig"}).

Currently, NVC is considered only in the classification criteria for SSc, with a weight of two points out of the nine points designated as the cut-off for a correct classification \[[@B30-diagnostics-10-00253]\]. Therefore, we performed a subgroup analysis on our diagnosed SSc patients. NVC was positive in 31 out of 32 patients, and it was fundamental in the classification of eight patients (25%). Indeed, six of these patients were seronegative for specific antibodies, and five did not have any skin involvement. [Table 3](#diagnostics-10-00253-t003){ref-type="table"} reports the clinical features of this small group of patients classified as SSc.

Taking patients with IIMs into account, we evaluated the role of NVC in predicting the disease. The comparison was made with patients in which IIMs were suspected (according to what was reported in the Methods section) but not confirmed. In this group of patients, the presence of RP was not associated with NVC+ (X^2^ 4.05; *p* = 0.44) As expected, high levels of CPK and positivity for IIM-specific antibodies were closely associated with IIMs (both *p* ≤ 0.0001), while NVC+, the presence of BCs, high levels of LDH and the presence of PMR symptoms did not show any significant results.

Taking into account only patients with amyopathic IIMs, we collected a subgroup of 18 patients and 25 controls. In this group, NVC positivity was more common in the IIM group than the control (X^2^ 9.53; *p* = 0.002). Similar results were obtained considering the presence of BCs (X^2^ 4.3; *p* = 0.03) and the presence of NVC+ or BCs (X^2^ 5.5; *p* = 0.01). However, considering the number of subjects involved in the subgroup analysis, the statistic power is limited (0.66).

4. Discussion {#sec4-diagnostics-10-00253}
=============

The differential diagnosis of ILDs as idiopathic or associated to CTDs is crucial. The prognosis of lung involvement in IPF is worse than CTDs, but these latter conditions can often show a systemic involvement that needs to be managed. The presence of signs and symptoms involving other organs is very useful for the correct diagnosis, but ILD patients may frequently have a poor clinical picture, and a specific classification is sometimes not possible. To overcome this problem, a large number of these patients are currently classified as IPAF. This research classification is aimed at recruiting patients with an incomplete form or the early onset of specific CTD involving the lung, resembling the concept of undifferentiated CTD. The classification criteria for this condition are strongly directed at diseases included in SSD or IIM; therefore, it is not surprising that, in a retrospective series, NVC was frequently found positive \[[@B31-diagnostics-10-00253]\]. However, in our prospective work, NVC+ is less common in IPAF \[[@B32-diagnostics-10-00253]\]. The present study confirms what has been previously observed: NVC+ in IPAF patients resulted similar to what was reported in RA; pSS (autoimmune diseases in which NVC+ is uncommon) and in non-autoimmune ILD patients (IPF, HP and cryptogenic).

This data can be explained by the prospective design of our study and the tight collaboration between rheumatologists and pulmonologists working together in our unit. As demonstrated in the present paper, NVC+ is frequently reported in ILD patients and strongly correlated with a diagnosis of CTD. Without NVC, a proportion of 25% of our ILD-SSc would have been classified as IPAF, making the proportion of NVC+ in the IPAF group significantly higher than what was reported in nonautoimmune ILD patients (e.g., IPF).

Nevertheless, in our study, a proportion of about 10% of IPAF patients have NVC+. In our opinion, all ILD-NVC+ patients, and mainly those classifiable as IPAF, should be carefully followed, looking for the possible onset of new features that can direct the diagnosis towards a specific CTD. The onset of ILD as the first manifestation of CTD is not uncommon, mainly for IIMs \[[@B33-diagnostics-10-00253]\], and a complete clinical picture (including myositis and inflammatory arthritis) will generally increase in the course of a few years \[[@B34-diagnostics-10-00253],[@B35-diagnostics-10-00253],[@B36-diagnostics-10-00253],[@B37-diagnostics-10-00253]\]. More rarely, ILD can be the first manifestation of SSc, even in the case with a complete clinical picture in a few years \[[@B3-diagnostics-10-00253],[@B33-diagnostics-10-00253]\], whereas a complete pSS can develop up to 10 years after ILD \[[@B38-diagnostics-10-00253]\].

Taking into account this data, as well as the prevalence of NVC+ in our whole ILD cohort, IPAF criteria might have benefits, including NVC as a possible "autoimmune feature" in ILD patients.

We also think that the classification of SSc patients in which NVC resulted crucial for the diagnosis is a main point of this study. Current SSc criteria improved the sensitivity in the classification of the patients, but a significant proportion of patients still do not reach the classification. In the interesting work by Jordan S. et al., SSc patients who did not meet classification criteria mainly had RP, SSc-related antibodies and NVC+, and only one patient had ILD \[[@B39-diagnostics-10-00253]\]. Conversely, in our study, we involved only ILD patients in order to confirm the predictive role of NVC in the diagnostic assessment of ILD. Clearly, according to the clinical features of patients reported in [Table 3](#diagnostics-10-00253-t003){ref-type="table"}, some diagnosis could be debatable. However, it should be taken into account that the gold standard for the diagnosis is based on the classification criteria and not the diagnostic ones. It is generally believed that ILD occurs in the advanced stages of SSc \[[@B40-diagnostics-10-00253]\]. However, this could be due to a selection bias, considering that ILD patients with mild rheumatologic signs can refer to a pulmonologist in order to treat the main problem. In these patients, the correct classification can be very difficult for nontrained physicians. Additionally, the same classification criteria could not perform in ILD patients as well as those reported in the rheumatology unit. Useful information in this topic can be produced by prospective studies on IPAF looking for possible developments of a definite form of SSc.

Moreover, although NVC is currently not considered in the classification criteria of IIMs, increased evidence supports a diagnostic role in this form, even if the patients are not-referred RP \[[@B12-diagnostics-10-00253]\]. This study confirms the lack of association between RP and NVC+, giving interesting results in amyopathic IIMs. We report for the first time the association of the presence of BCs and/or GCs in ILD with an amyopathic form of IIMs independently of the presence of RP. A suspicion of myositis in ILD patients without increased levels of CPK can be very difficult, considering also that the asthenia could apparently be better explained by lung involvement. These patients rarely undergo NVC, considering the possible absence of RP. The inclusion of NVC in the first-line assessment of ILD patients might produce information able to support IIM diagnosis, avoiding incorrect classification of these patients as IPAF.

The present study has some limits. First of all, we used the international consensus criteria for the definition of the presence of RP. As stated by the same authors, provocation tests are informative but could cause patient injuries, while thermographic imaging and laser doppler flowmetry have questionable utility \[[@B14-diagnostics-10-00253]\]. Moreover, although the group of patients enrolled was sufficient to achieve confidence regarding the prevalence of NVC+ in ILD patients, the subgroup analysis in IIM had limited power and should be considered with caution. IIMs are very rare conditions, and new, larger studies will be useful to support our findings.

In conclusion, NVC is an easy tool that is able to safely and rapidly address a specific diagnosis, mainly for SSc and IIMs. Its diagnostic role can have value in ILD patients, considering that these two conditions are associated with the worst prognosis in CTD-ILD. Together with the clinical assessment, the current available and new, emerging blood biomarkers \[[@B41-diagnostics-10-00253],[@B42-diagnostics-10-00253]\], NVC could be considered as a tool in the first-line diagnostic procedure in ILD patients independently of the presence of RP.
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![Description of Nailfold videocapillaroscopy. (**A**) Normal pattern, (**B**) presence of giant capillaries, (**C**) avascular area with single microhemorrhage and (**D**--**F**): bushy capillaries.](diagnostics-10-00253-g001){#diagnostics-10-00253-f001}

![Proportion of nailfold videocapillaroscopy (NVC) positivity for each diagnosis in interstitial lung disease (ILD) patients. ASAS: antisynthetase syndromes, HP: hypersensitivity pneumonia, IPAF: interstitial pneumonia with autoimmune features, IPF: idiopathic pulmonary fibrosis, MCTD: mixed connective tissue disease, NVC: nailfold videocapillaroscopy, PM/DM: polymyositis/dermatomyositis, pSS: primary Sjӧgren's syndrome, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus and SSc: systemic sclerosis.](diagnostics-10-00253-g002){#diagnostics-10-00253-f002}

diagnostics-10-00253-t001_Table 1

###### 

Characteristics of the interstitial lung disease (ILD) cohort studied.

  ----------------------------------------------------------------------------------------------------
  General Features   HRCT Pattern   Final Diagnosis                               
  ------------------ -------------- ----------------- ------- ------------------- --------------------
  Number\            361 (52%)      NSIP              39.3%   IPF                 24.3%
  (% Female)                                                                      

  Age                66.6 (±10.8)   OP                7.2%    HP                  4.2%

  RP                 95 (26.3%)     UIPp              12.5%   Exposure            5%

  NVC +              64 (17.7%)     UIP               24.6%   IIMs (PM/DM+ASAS)   8.6% (3.9% + 4.7%)

                                    CPFE              4.7%    SSDs (SSc+MCTD)     8.3% (7.7% + 0.5%)

                                    DIP               3%      RA                  6.6%

                                    LIP               0.6%    pSS                 4.7%

                                    Undetermined      10.2%   SLE                 0.5%

                                    Combined \#       0.9%    Overlap §           2.2%

                                                              IPAF                17.5%

                                                              Other \*            0.8%

                                                              Cryptogenic         17.7%
  ----------------------------------------------------------------------------------------------------

RP: Raynaud's phenomenon; NVC: nailfold videocapillaroscopy; IPF: idiopathic pulmonary fibrosis; HP: hypersensitivity pneumonia; IIMs: idiopathic inflammatory myopathies; SSDs: scleroderma spectrum disorders; IPAF: interstitial pneumonia with autoimmune features; ASAS: antisynthetase antibody syndrome; CPFE: combined pulmonary fibrosis and emphysema; DIP: desquamative interstitial pneumonia; HRCT: high-resolution computed tomography; LIP: lymphocytic interstitial pneumonia; MCTD: mixed connective tissue disease; NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; PM/DM: poly/dermatomyositis; pSS: primary Sjögren's syndrome; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; UIP: usual interstitial pneumonia; UIPp: possible UIP; **\#** = NSIP+OP: 1 patient; UIP+OP: 2 patients; § = 3 patients with PM+SSc; 1 patient for each overlap syndromes: ASAS+SS, PM+SS, RA+SS, SLE+SSc and SSc+SS; **\*** = granulomatosis with polyangiitis: 2 patients and common variable immunodeficiency: 1 patient.

diagnostics-10-00253-t002_Table 2

###### 

Comparison between ILD patients with and without NVC positivity.

  Items              NVC+Patients   NVC-Patients   *p*
  ------------------ -------------- -------------- ----------
  Number             64             297            
  Mean Age (± SD)    61.4 ± 13.3    67.8 ± 9.8     0.001
  Female%            65.6           49.1           0.01
  RP%                68.7           17.1           \<0.0001
  HRCT patterns%                                   
  NSIP               51.5           36.4           0.02
  OP                 3.1            8              n.s.
  NSIP+OP            0              0.4            n.s.
  UIP                18.75          25.9           n.s.
  UIP+OP             1.5            0.4            n.s.
  UIPp               9.4            13.1           n.s.
  CPFE               1.5            5.4            n.s.
  DIP                1.5            3.4            n.s.
  LIP                1.5            0.4            n.s.
  Indeterminate      10.9           6.7            n.s.
  Final Diagnosis%                                 
  SSDs               45.3           1              \<0.0001
  IIMs               25             6.4            \<0.0001
  Other CTDs \#      6.2            13.5           n.s.
  IPAF               10.9           19.5           n.s.
  IPF                7.8            27.9           0.0007
  Other \*           3              31.6           \<0.0001

n.s.: not significant. Other connective tissue diseases (CTD)\# = in NVC+ patients: primary Sjögren's syndrome (pSS) 4.6% + systemic lupus erythematosus (SLE) 1.5% and in NVC- patients: pSS 4.7% + SLE 0.4% + rheumatoid arthritis 8.4%. Other\* = in NVC+ patients: 1.5% for each smoke-related, cryptogenic NSIP and UIPp and, in NVC- patients: hypersensitivity pneumonia 5% + granulomatosis with polyangiitis 0.6% + common variable immunodeficiency 0.3% + environmental 0.9% + drug 2.7% + smoke 1.8% + cryptogenic NSIP 9.4% + OP 2.7% and UIPp 9.1% + CPFE 1.7%.

diagnostics-10-00253-t003_Table 3

###### 

Clinical features of SSc patients in which NVC resulted determinant for the classification.

  Patients   RP   ILD/PAH   T   FTLs   Skin   Abs   NVC+   Total
  ---------- ---- --------- --- ------ ------ ----- ------ -------
  **P1**     0    2         2   3      0      0     2      9
  **P2**     3    2         0   3      0      0     2      10
  **P3**     3    2         0   0      2      0     2      9
  **P4**     3    2         2   0      0      0     2      9
  **P5**     3    2         0   0      2      0     2      9
  **P6**     3    2         0   0      2      0     2      9
  **P7**     3    2         0   0      0      3     2      10
  **P8**     3    2         0   0      0      3     2      10

Abs: autoantibodies, ILD: interstitial lung diseases, FTLs: fingertip lesions, NVC+: nailfold videocapillaroscopy positivity, PAH: pulmonary artery hypertension, RP: Raynaud's phenomenon, Skin: skin involvement and T: telangiectasia. According to SSc classification criteria \[[@B27-diagnostics-10-00253]\], patients can be classified with a minimum of 9 points. FTL can be weighted with 2 or 3 points based on the presence of distal tip ulcers or pitting scars. Skin involvement can be weighted with 2, 4 or 9 points based on its extension. Presence of ILD/PAH, T and NVC+ have a value of 2 points, while specific Abs are 3 points.

[^1]: These authors contributed equally to this work.
